Format
Sort by
Items per page

Send to

Choose Destination

Best matches for fluoxetine/AE OR Olanzapine/AE OR Fluoxetine/AE:

Olanzapine plus fluoxetine for bipolar disorder: a systematic review and meta-analysis. Silva MT et al. J Affect Disord. (2013)

Drug safety evaluation of olanzapine/fluoxetine combination. Cristancho MA et al. Expert Opin Drug Saf. (2014)

Olanzapine-fluoxetine combination for the treatment of bipolar depression. Citrome L et al. Expert Opin Pharmacother. (2011)

Search results

Items: 1 to 20 of 5818

1.

DoE based Olanzapine loaded poly-caprolactone nanoparticles decreases extrapyramidal effects in rodent model.

Joseph E, Reddi S, Rinwa V, Balwani G, Saha R.

Int J Pharm. 2018 Feb 20. pii: S0378-5173(18)30085-1. doi: 10.1016/j.ijpharm.2018.02.010. [Epub ahead of print]

PMID:
29474898
2.

Antipsychotic Prescriptions Among Adults With Major Depressive Disorder in Office-Based Outpatient Settings: National Trends From 2006 to 2015.

Rhee TG, Mohamed S, Rosenheck RA.

J Clin Psychiatry. 2018 Feb 13;79(2). pii: 17m11970. doi: 10.4088/JCP.17m11970. [Epub ahead of print]

PMID:
29469245
3.

Olanzapine-induced peripheral eosinophilia and eosinophilic pleural effusion: A case report.

Huang J, Yu Y, Lin W, Zhang D, Deng Z, Ding Q.

Medicine (Baltimore). 2018 Feb;97(7):e9996. doi: 10.1097/MD.0000000000009996.

4.

Therapeutic drug monitoring of atypical antipsychotics.

Urban AE, Cubała WJ.

Psychiatr Pol. 2017 Dec 30;51(6):1059-1077. doi: 10.12740/PP/65307. Epub 2017 Dec 30. Review. English, Polish.

5.

Serum IL-1ra, a novel biomarker predicting olanzapine-induced hypercholesterolemia and hyperleptinemia in schizophrenia.

Lin Y, Peng Y, He S, Xu J, Shi Y, Su Y, Zhu C, Zhang X, Zhou R, Cui D.

Prog Neuropsychopharmacol Biol Psychiatry. 2018 Feb 1;84(Pt A):71-78. doi: 10.1016/j.pnpbp.2018.01.020. [Epub ahead of print]

6.

The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment.

Raben AT, Marshe VS, Chintoh A, Gorbovskaya I, Müller DJ, Hahn MK.

Front Neurosci. 2018 Jan 22;11:741. doi: 10.3389/fnins.2017.00741. eCollection 2017. Review.

7.

Control of Nausea and Vomiting in Patients Receiving Anthracycline/Cyclophosphamide Chemotherapy for Breast Cancer.

Nawa-Nishigaki M, Kobayashi R, Suzuki A, Hirose C, Matsuoka R, Mori R, Futamura M, Sugiyama T, Yoshida K, Itoh Y.

Anticancer Res. 2018 Feb;38(2):877-884.

PMID:
29374715
8.

The incidence, psychiatric co-morbidity and pharmacological treatment of severe mental disorders in children and adolescents.

Nesvåg R, Bramness JG, Handal M, Hartz I, Hjellvik V, Skurtveit S.

Eur Psychiatry. 2018 Jan 20;49:16-22. doi: 10.1016/j.eurpsy.2017.12.009. [Epub ahead of print]

PMID:
29366845
9.

Olanzapine Versus Risperidone in Children and Adolescents with Psychosis: A Meta-Analysis of Randomized Controlled Trials.

Xia L, Li WZ, Liu HZ, Hao R, Zhang XY.

J Child Adolesc Psychopharmacol. 2018 Jan 22. doi: 10.1089/cap.2017.0120. [Epub ahead of print]

PMID:
29356569
10.

Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse.

Temmingh HS, Williams T, Siegfried N, Stein DJ.

Cochrane Database Syst Rev. 2018 Jan 22;1:CD011057. doi: 10.1002/14651858.CD011057.pub2. Review.

PMID:
29355909
11.

Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation).

Ostinelli EG, Jajawi S, Spyridi S, Sayal K, Jayaram MB.

Cochrane Database Syst Rev. 2018 Jan 8;1:CD008074. doi: 10.1002/14651858.CD008074.pub2. Review.

PMID:
29308601
12.

The efficacy, acceptability, and safety of five atypical antipsychotics in patients with first-episode drug-naïve schizophrenia: a randomized comparative trial.

Wang C, Shi W, Huang C, Zhu J, Huang W, Chen G.

Ann Gen Psychiatry. 2017 Dec 22;16:47. doi: 10.1186/s12991-017-0170-2. eCollection 2017.

13.

Olanzapine-induced Psoriasis.

Chepure AH, Ungratwar AK.

Indian J Psychol Med. 2017 Nov-Dec;39(6):811-812. doi: 10.4103/IJPSYM.IJPSYM_21_17.

15.

Diving and antidepressants.

Querido AL.

Diving Hyperb Med. 2017 Dec;47(4):253-256. doi: 10.28920/dhm47.4.253-256. Review.

PMID:
29241236
16.

Potential diagnostic markers of olanzapine efficiency for acute psychosis: a focus on peripheral biogenic amines.

Taraskina AE, Nasyrova RF, Zabotina AM, Sosin DN, Sosina КА, Ershov EE, Grunina MN, Krupitsky EM.

BMC Psychiatry. 2017 Dec 8;17(1):394. doi: 10.1186/s12888-017-1562-1.

17.

Benzodiazepines for psychosis-induced aggression or agitation.

Zaman H, Sampson SJ, Beck AL, Sharma T, Clay FJ, Spyridi S, Zhao S, Gillies D.

Cochrane Database Syst Rev. 2017 Dec 8;12:CD003079. doi: 10.1002/14651858.CD003079.pub4. [Epub ahead of print] Review.

PMID:
29219171
18.

Is There a Potential of Misuse for Quetiapine?: Literature Review and Analysis of the European Medicines Agency/European Medicines Agency Adverse Drug Reactions' Database.

Chiappini S, Schifano F.

J Clin Psychopharmacol. 2018 Feb;38(1):72-79. doi: 10.1097/JCP.0000000000000814. Review.

PMID:
29210868
19.

Reversal of olanzapine-induced weight gain in a patient with schizophrenia by switching to asenapine: a case report.

Okazaki K, Yamamuro K, Kishimoto T.

Neuropsychiatr Dis Treat. 2017 Nov 21;13:2837-2840. doi: 10.2147/NDT.S148616. eCollection 2017.

20.

The protective effect of thymoquinone over olanzapine-induced side effects in liver, and metabolic side effects.

Bilgic S, Tastemir Korkmaz D, Azirak S, Guvenc AN, Kocaman N, Ozer MK.

Bratisl Lek Listy. 2017;118(10):618-625. doi: 10.4149/BLL_2017_119.

PMID:
29198130

Supplemental Content

Loading ...
Support Center